Cardiotoxicity in Breast Cancer Therapy: Risks, Mechanisms, and Prevention Strategies
Medical Sciences · 2025
DOI: 10.3390/medsci13030130 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical Sciences, 2025. Verfasst von Annisa Eka Fitrianti und 6 weiteren Autor:innen. Beteiligte Einrichtung: Master's Program in Pharmacy, School of Pharmacy, Institut Teknologi Bandung, Bandung 40132, Indonesia. Hauptthemen laut MEDLINE: Breast Neoplasms, Cardiotoxicity, Antineoplastic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 156 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 2024 Research, Community Service, and Innovation (PPMI 2024) Program, School of Pharmacy, Institut Teknologi Bandung.
Abstract (Originalsprache)
Breast cancer is the most prevalent cancer in women. Anthracyclines are commonly used as the first line of treatment, often combined with other agents, including trastuzumab. Despite their efficacy, both drugs pose a risk of cardiotoxicity, which may impair patients’ quality of life (QoL) and hinder treatment persistence. Anthracycline-induced cardiotoxicity is dose-dependent and generally irreversible, whereas trastuzumab is associated with potentially reversible cardiac dysfunction. This review discusses the risk factors and biological mechanisms underlying chemotherapy-induced cardiotoxicity in breast cancer and explores effective strategies for prevention and treatment. It has been demonstrated that several cardioprotective strategies, such as treatments with angiotensin-converting enzyme inhibitors (ACEis), angiotensin receptor blockers (ARBs), beta-blockers, and dexrazoxane, can help lessen cardiotoxic effects. A better understanding of cardioprotective strategies may help optimize cancer treatment without compromising cardiovascular function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Master's Program in Pharmacy, School of Pharmacy, Institut Teknologi Bandung, Bandung 40132, Indonesia.
- Department of Pharmacy, Dr. Hasan Sadikin General Hospital, Bandung 40161, Indonesia.
- Department of Cardiology, Dr. Hasan Sadikin General Hospital, Bandung 40161, Indonesia.
- Department of Pharmacology-Clinical Pharmacy, Institut Teknologi Bandung, Bandung 40132, Indonesia.
- Department of Pharmacy, Dharmais Cancer Hospital, Jakarta 11420, Indonesia.
ORCID-Profile: Kusnandar Anggadiredja, Zulfan Zazuli
Förderung
- 2024 Research, Community Service, and Innovation (PPMI 2024) Program, School of Pharmacy, Institut Teknologi Bandung
Zitieren
APA
Fitrianti, A. E., Wardani, N. O., Astuti, A., Anggadiredja, K., Amalia, L., Putri, R. A., & Zazuli, Z. (2025). Cardiotoxicity in Breast Cancer Therapy: Risks, Mechanisms, and Prevention Strategies. Medical Sciences. https://doi.org/10.3390/medsci13030130
Vancouver
Fitrianti AE, Wardani NO, Astuti A, Anggadiredja K, Amalia L, Putri RA, et al. Cardiotoxicity in Breast Cancer Therapy: Risks, Mechanisms, and Prevention Strategies. Medical Sciences. 2025. doi:10.3390/medsci13030130
BibTeX
@article{Fitrianti2025,
author = {Fitrianti, Annisa Eka and Wardani, Nadea Olyvia and Astuti, Astri and Anggadiredja, Kusnandar and Amalia, Lia and Putri, Risani Andalasia and Zazuli, Zulfan},
title = {Cardiotoxicity in Breast Cancer Therapy: Risks, Mechanisms, and Prevention Strategies},
journal = {Medical Sciences},
year = {2025},
doi = {10.3390/medsci13030130}
}
EUVIMED